JP2025501978A5 - - Google Patents
Info
- Publication number
- JP2025501978A5 JP2025501978A5 JP2024539848A JP2024539848A JP2025501978A5 JP 2025501978 A5 JP2025501978 A5 JP 2025501978A5 JP 2024539848 A JP2024539848 A JP 2024539848A JP 2024539848 A JP2024539848 A JP 2024539848A JP 2025501978 A5 JP2025501978 A5 JP 2025501978A5
- Authority
- JP
- Japan
- Prior art keywords
- adc
- amino acid
- pharmaceutical product
- subject
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296831P | 2022-01-05 | 2022-01-05 | |
| US63/296,831 | 2022-01-05 | ||
| US202263304136P | 2022-01-28 | 2022-01-28 | |
| US63/304,136 | 2022-01-28 | ||
| PCT/US2023/060062 WO2023133388A2 (en) | 2022-01-05 | 2023-01-04 | Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501978A JP2025501978A (ja) | 2025-01-24 |
| JP2025501978A5 true JP2025501978A5 (OSRAM) | 2026-01-08 |
Family
ID=87074240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024539848A Pending JP2025501978A (ja) | 2022-01-05 | 2023-01-04 | １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）で筋層浸潤性尿路上皮癌または筋層浸潤性膀胱癌を治療するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250064956A1 (OSRAM) |
| EP (1) | EP4460332A2 (OSRAM) |
| JP (1) | JP2025501978A (OSRAM) |
| KR (1) | KR20240137135A (OSRAM) |
| CN (1) | CN119838023A (OSRAM) |
| AU (1) | AU2023205782A1 (OSRAM) |
| CA (1) | CA3242837A1 (OSRAM) |
| IL (1) | IL313915A (OSRAM) |
| MX (1) | MX2024008174A (OSRAM) |
| TW (1) | TW202333801A (OSRAM) |
| WO (1) | WO2023133388A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| WO2025021073A1 (zh) * | 2023-07-21 | 2025-01-30 | 江苏迈威康新药研发有限公司 | 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途 |
| WO2025064741A1 (en) * | 2023-09-21 | 2025-03-27 | Agensys, Inc. | Treating locally advanced or metastatic urothelial cancer with anti-191p4d12 antibody drug conjugates in combination with pembrolizumab |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150292030A1 (en) * | 2012-11-27 | 2015-10-15 | Board Of Regents, The University Of Texas System | Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer |
-
2023
- 2023-01-04 JP JP2024539848A patent/JP2025501978A/ja active Pending
- 2023-01-04 US US18/724,594 patent/US20250064956A1/en active Pending
- 2023-01-04 CA CA3242837A patent/CA3242837A1/en active Pending
- 2023-01-04 WO PCT/US2023/060062 patent/WO2023133388A2/en not_active Ceased
- 2023-01-04 EP EP23737701.5A patent/EP4460332A2/en active Pending
- 2023-01-04 IL IL313915A patent/IL313915A/en unknown
- 2023-01-04 TW TW112100235A patent/TW202333801A/zh unknown
- 2023-01-04 KR KR1020247026352A patent/KR20240137135A/ko active Pending
- 2023-01-04 CN CN202510006527.3A patent/CN119838023A/zh active Pending
- 2023-01-04 AU AU2023205782A patent/AU2023205782A1/en active Pending
-
2024
- 2024-06-27 MX MX2024008174A patent/MX2024008174A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501978A5 (OSRAM) | ||
| KR101320198B1 (ko) | 신생물의 치료를 위한 조성물 및 방법 | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| JP2021523158A5 (OSRAM) | ||
| JP2021518394A5 (OSRAM) | ||
| JP2021515017A5 (OSRAM) | ||
| JP2021523233A5 (OSRAM) | ||
| CN103547596A (zh) | 抗-cd19类美登素免疫缀合物抗体在治疗b-细胞恶性肿瘤症状中的用途 | |
| US11325980B2 (en) | Combination therapy using a LIV1-ADC and a chemotherapeutic | |
| JP2021501776A5 (OSRAM) | ||
| JP2022513386A5 (OSRAM) | ||
| JP2022541591A5 (OSRAM) | ||
| JP2021534165A5 (OSRAM) | ||
| JP2022544227A5 (OSRAM) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023500888A5 (OSRAM) | ||
| JP2023500697A5 (OSRAM) | ||
| JP2023542879A5 (OSRAM) | ||
| JP2023545432A5 (OSRAM) | ||
| EP3896089A1 (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
| JP7750902B2 (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2023500480A5 (OSRAM) | ||
| JP2022520572A (ja) | 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 |